Diagnosis and Monitoring of &lt;I&gt;PML-RARA&lt;/I&gt;-Positive Acute Promyelocytic Leukemia by Qualitative RT-PCR

Rossi, Vincenzo; Levati, Laura; Biondi, Andrea

doi:10.1385/1-59745-017-0:115

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second breakpoint (BCR2) at exon 6 will result in variable transcripts, which can be of different sizes in different patients and, therefore, are called variable form (also called type C). The third breakpoint (BCR3) at intron 3 will result in a short transcript (also called type A) [32][33][34][35] . Normally, different primers are needed to target different isoforms due to the different breakpoints on PML.…”

Section: Examples Of Aml Mutation Tests Aplmentioning

confidence: 99%

Molecular testing for acute myeloid leukemia

Qin¹

2021

Cancer Biol. Med.

View full text Add to dashboard Cite

In the era of personalized medicine, information on molecular change at the gene level is important for patient care. Such information has been used for disease classification, diagnosis, prognosis, risk stratification, and treatment, which is especially important in cancer patient care. Many molecular tests exist and can be used to detect the molecular changes at gene level. These tests include, but are not limited to, karyotyping, endpoint polymerase chain reaction (PCR), real-time PCR, Sanger sequencing, pyrosequencing, nextgeneration sequencing, and so forth. How to use the right tests for the right patients at the right time is essential for optimal patient outcome. This review puts together some information on molecular testing for acute myeloid leukemia.

show abstract

Section: Examples Of Aml Mutation Tests Aplmentioning

confidence: 99%